Preloader

Support in Central and Eastern Europe (CEE) & European HTA Database

Econmed
Econmed

See Database Demo

Ogólnoeuropejska baza dokumentacji HTA

Umożliwiająca przygotowanie do Joint Clinical Assessment

Pan-European HTA Documentation Database

Through our collaboration with Accessus Health GmbH, we offer access to the European HTA Database – a unique tool supporting preparation for the EU Joint Clinical Assessment and local Market Access processes across Europe.

Econmed
Discover Our Solution
Econmed
Econmed

Scope

  • Database of HTA procedure documents from all key European markets
  • Documents covering clinical evidence assessment, pricing and reimbursement, and economic evaluations
  • National and EU-level HTA procedures for centrally authorized products
  • Monthly updates
Econmed

Key Features

  • Access anytime, anywhere
  • Intuitive navigation with a user-friendly interface
  • Targeted searches with multiple filters
  • High sensitivity: full-text search across all HTA documents
FIND MORE SEE DEMO
Econmed

Local Experts, Unified Methodology

This core principle of the network applies to the European HTA Database as well: data is collected by local network partners with country-specific HTA expertise, following a single unified methodology to provide reliable and comprehensive HTA information across Europe.

Econmed

Support in Central and Eastern Europe (CEE)

At EconMed Europe, we specialize in providing comprehensive Market Access, HTA, and HEOR support in the dynamic CEE markets. With over 10 years of experience and close collaboration with local experts, we help pharmaceutical and medical device companies navigate the complex reimbursement systems of more than 20 countries in the region.

Why Work with Us?

  • Global Value Dossier (GVD) adaptation of global materials and models to local conditions (including CEA, BIA).
  • Market Access Strategies development of effective, locally tailored market entry plans.
  • HTA and Reimbursement Support preparation and submission of HTA dossiers leading to positive reimbursement decisions.
  • Market Potential Analyses including orphan drugs, leveraging interviews with local clinicians and payers.

Our advantage lies in combining local knowledge and understanding of CEE markets with an international perspective and experience.